Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report

doi:10.4251/wjgo.v17.i4.102258

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (495)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

HTML

327

Figures (1-4)

Sum=405

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=57

Apr 15, 2025 (publication date) through Apr 18, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 102258
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102258

Full Size Figure Download Figure

Figure 4 Dynamics of carcinoembryonic antigen, alpha-fetoprotein, and cancer antigen 19-9 and timeline of treatment options. A-C: Diagram depicting the dynamic of carcinoembryonic antigen (A), alpha-fetoprotein (B) and cancer antigen 19-9 (C); D: The timeline of the treatment protocol. CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein; CA19-9: Cancer antigen 19-9; IHC: Immunohistochemistry; CT: Computed tomography; AEs: Adverse events; GC: Gastric cancer; PR: Partial response; BMI: Body mass index; pCR: Pathological complete response; PFS: Progression-free survival; OS: Overall survival.

Citation: Du XY, Xia RJ, Shen LW, Ma JG, Yao WQ, Xu W, Lin ZP, Ma LB, Niu GQ, Fan RF, Xu SM, Yan L. Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report. World J Gastrointest Oncol 2025; 17(4): 102258
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/102258.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.102258